Current funding opportunities related to TB and HIV, expired RFAs will be hidden after closing date. Sort using the tags menu to the right.
For funding opportunities related to global health, please see the Vanderbilt Institute for Global Health announcements found here.
September 2021 NIAID Council-Approved Concepts
Improved Drug Susceptibility Testing (DST) for Tuberculosis!
Request for Applications—proposed FY 2023 initiative
Objective: To support the development of new diagnostic technologies for tuberculosis (TB) drug susceptibility testing (DST), including point-of-care DST and companion diagnostics for new TB drugs.
Description: This concept would further the development of new diagnostic technologies for TB DST with an emphasis on rapid, point-of-care, low complexity assays. As new drugs move forward in the pipeline, there is a need for companion DST diagnostics for new drugs to ensure new drugs are used most effectively. Current phenotypic methods for determining drug resistance (DR) provide clinically relevant drug susceptibility information but have limitations. For example, the gold standard relies on culture, requires time for growth, and does not provide a result for many days. The program would solicit highly innovative DST assays, including phenotypic DST that may rely on a readout that does not require full growth as in traditional DST assays. Innovative technologies beyond nucleic acid amplification tests will be encouraged. This effort is anticipated to include exploratory work that would further improve our knowledge of genotypic and phenotypic correlates of clinical DR, which can be complex. Research that leverages the rapid advances in diagnostic technologies for COVID-19 applied to TB are also encouraged. Furthermore, this effort would be targeted to technology holders partnered with academic, clinical, and laboratory colleagues with TB diagnostic expertise.
Contact: Karen Lacourciere
240-627-3297
Click here for more information!
NIAID Funding Opportunity: Brazil Regional Prospective Observational Research in Tuberculosis
Brazil Regional Prospective Observational Research in Tuberculosis (RePORT) (U01 Clinical Trial Not Allowed)
Application open date: November 08, 2021
Expiration Date: December 09, 2021
The purpose of this Funding Opportunity Announcement (FOA) is to support a Brazil-US Regional Prospective Observational Research in Tuberculosis (RePORT) network to advance TB and TB/HIV science. The RePORT Brazil network will leverage and build upon Brazilian cohorts currently following adult and pediatric populations with active TB disease and their contacts or other high TB-risk individuals to address key research questions of regional and global interest. Specific areas supported under this program include, but are not limited to, research and development projects in TB/HIV in the areas of molecular epidemiology, diagnostics, biomarkers, vaccine development, and the impact of co-morbidities such as HIV and diabetes. Research outcomes should be capable of advancing tools with public health impact or of influencing decision making in TB public health to inform stakeholders on the best practices for early prevention, diagnosis, and clinical management of TB and TB/HIV.
Click here for more information about this funding opportunity!
June 2021 DAIDS Council-Approved Concepts
Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. Concepts reveal possible initiatives or give you ideas for an investigator-initiated application.
FY 2022 Concepts
- Brazil Regional Prospective Observational Research in Tuberculosis (RePORT)
Objective: The primary objective of this initiative is to enable a network of Brazilian and U.S. scientists to advance current understanding of the community, host, and microbial factors that impact outcomes of tuberculosis (TB) infection and TB disease, especially among persons with HIV (PWH), including drug-resistant (DR)-TB, to facilitate developing tools to improve treatment outcomes at the individual level and inform strategies to curtail the TB epidemic at the public health level.
To achieve this, the initiative will support a Brazil-U.S. Regional Prospective Observational Research in Tuberculosis (RePORT) network that will leverage the robust clinical research infrastructure that exists within Brazil to capacitate a wide range of research.
Contact: Dr Sudha Srinivasan
FY 2023 Concepts
- South Africa Regional Prospective Observational Research in Tuberculosis (RePORT)
Objective: The primary objective of this initiative is to enable a network of South African and U.S. scientists to advance current understanding of the community, host, and microbial factors that impact outcomes of tuberculosis (TB) infection and TB disease, especially among persons with HIV (PWH), including drug-resistant TB, to facilitate development of tools to improve treatment outcomes at the individual level and to inform strategies to curtail the TB epidemic at the public health level.
To achieve this, the initiative will support a South Africa-U.S. Regional Prospective Observational Research in Tuberculosis (RePORT) network that will leverage the robust clinical research infrastructure that exists within South Africa to capacitate this research.
Contact: Dr Sudha Srinivasan
- RePORT International Coordinating Center (RICC)
Objective: The primary objective of this initiative is to advance tuberculosis (TB) and TB/HIV research by supporting coordination of global research efforts undertaken by the various in-country Regional Prospective Observational Research for Tuberculosis (RePORT) networks and other research partners. The RePORT International Coordinating Center (RICC) enables coordination and acceleration of research across the six RePORT countries (India, Brazil, South Africa, China, Indonesia, and Philippines) and fosters a synergistic approach. This will allow for maximizing resources, validating research findings, and generating globally applicable research outcomes in a timely manner.
Contact: Dr Sudha Srinivasan
- Biomarker Signatures of Tuberculosis Infection in Young Children With and Without HIV
Objective: The goal of this initiative is to advance research to discover and validate novel biomarkers of tuberculosis (TB) infection and subsequent risk of progression to TB disease in young children with and without HIV.
Contact: Patrick Jean-Philippe
Click here for more information!
Advancing Vaccine Adjuvant Research for Tuberculosis (TB)
Solicitation for BAA-DAIT-75N93021R00008 entitled, "Advancing Vaccine Adjuvant Research for Tuberculosis (TB)"
Contract Opportunity Type: Solicitation
The goal of this program is to further the development of TB vaccines through sideby-side comparisons of adjuvants in combination with TB immunogens, and to establish immunological profiles of adjuvants that work through different mechanisms, facilitating the identification of the most promising adjuvant:Mtb immunogen candidates for clinical development and potential immune correlates of protection. The range of adjuvants to be evaluated may include novel classes of adjuvants being developed for other infections and immune-oncology therapeutics, as well as adjuvants already being developed for TB vaccines. It is anticipated that one cost reimbursement, completion type contract will be awarded for a five [5]-year period of performance beginning on or about 7/22/22.
NIAID anticipates that the average annual total cost (direct and indirect costs combined) is $4 million per contract. However, it is anticipated that the total cost for the award(s) may vary depending upon the scope of the project and the technical objectives of the award(s). The length of time for which funding is requested should be consistent with the nature and complexity of the proposed research. In no event shall the period of performance proposed by an offeror exceed five [5] years. Any responsible offeror may submit a proposal which shall be considered by the Agency. This BAA will be available electronically on/about April, 28, 2021, and may be accessed through here. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.
Published: Apr 28, 2021 12:41 pm EDT
Offers Due: Aug 10, 2021 03:00 pm EDT
Postdoctoral Fellowship opportunity in Global HIV & TB Research
Post-Doctoral Research Fellowships for Global HIV and TB Public Health Programs
The mission of this fellowship program is to recruit, mentor, and train scientist-practitioners to conduct global HIV and TB research and to develop the translational and applied skills necessary to implement and support high-quality HIV and TB public health programs in global settings. The goal of this fellowship is to attract and support recent recipients of doctoral degrees to understand the underpinnings of interventional epidemiology and to prepare them for a career operating at the intersection of science and practice in global public health. The selected candidates will be in the Division of Global HIV & TB (DGHT) at the Centers for Disease Control and Prevention (CDC), headquartered in Atlanta, GA. The DGHT Office of the Director (DGHT OD) is the lead for the program. Fellows will also be paired with DGHT’s programmatic or data branches on various projects throughout their fellowship.
The deadline to apply to this fellowship is June 30, 2021. The fellowship is scheduled to begin Fall 2021, subject to availability of funds.
Click here for more information about this fellowship!
Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed)
Application Due Date: June 30, 2021. Letter of Intent Due Date: 30 days prior to the application due date. Expires: July 01, 2021.
The purpose of this funding opportunity is to support the design of novel tuberculosis (TB) vaccine candidates that exploit innovative approaches and their advancement into preclinical animal model testing. This funding opportunity will use a milestone driven, biphasic award mechanism to fund high risk/exploratory research. Transition to the second phase depends on the successful completion of milestones.
Notice of Special Interest (NOSI): Secondary Analysis of Existing Datasets for Advancing Immune-mediated and Infectious Disease Research
First Application Due Date: June 16, 2021. Expires: May 8, 2024.
This Notice of Special Interest (NOSI) is to support projects that use data, alone or in combination, to address scientific questions and knowledge gaps in basic or clinical research in immune-mediated and infectious diseases.
Must submit to: PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
https://grants.nih.gov/grants/guide/notice-files/NOT-AI-21-011.html
Supporting, Mobilizing, and Accelerating Research for TB Elimination (SMART4TB)
Application Due Date: Pending
The goals of this planned award are:
1) to stimulate the development and implementation of new tools and approaches to accelerate the prevention, detection and management of tuberculosis in adults and children and
2) strengthen local capacity to design, implement, disseminate and use findings from TB research.
Anticipated Award Date: 9/30/2021
https://www.usaid.gov/business-forecast/search/award/89532a8c84?search=&location=All&ouid=All&page=9
Tuberculosis Research Advancement Centers (P30 Clinical Trials Not Allowed), expires June 16, 2021
Application Due Date: June 15, 2021
The purpose of this Funding Opportunity Announcement (FOA) is to solicit meritorious applications for the Tuberculosis Research Advancement Centers (TRACs) program. The main goal of these centers is to provide administrative and shared research support to foster and elevate multidisciplinary tuberculosis (TB) research and provide exceptional mentorship to New Investigators. TRACs will provide core facilities, services and mentoring opportunities to achieve the goals of the program.
https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-001.html
Using Syndemics to Understand HLBS Disease Emergence and Progression in People with HIV (PWH)(R01 Clinical Trial Not Allowed), expires 12/15/2021
Application Due Date(s): January 11, 2021, and December 14, 2021
This funding opportunity announcement is intended to support research project grant (R01) applications that propose to utilize a syndemics (synergistic epidemic) framework to elucidate the role of social, economic, environmental, behavioral, structural, psychological factors in promoting the synergistic interactions and clustering of heart, lung, blood, and sleep (HLBS) comorbidities among people with HIV at the population level. The ultimate goal is to identify strategies that foster holistic approaches in the clinical management of people living with HIV who have HLBS comorbidities, and to utilize existing data to assess the feasibility and cost-effectiveness of such approaches.
https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-21-018.html